TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from PYC Therapeutics Limited ( (AU:PYC) ) is now available.
PYC Therapeutics Limited has provided an update on its business operations, emphasizing its drug development pipeline. The company’s investigational drug candidates are still under development and have not received regulatory approval, highlighting the ongoing risks and uncertainties in its operations.
The most recent analyst rating on (AU:PYC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
More about PYC Therapeutics Limited
PYC Therapeutics Limited operates in the biotechnology industry, focusing on drug development. The company is engaged in creating investigational drug candidates, which are not yet approved by any regulatory authority.
Average Trading Volume: 702,200
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$799.1M
See more insights into PYC stock on TipRanks’ Stock Analysis page.